Cardiac Signaling Lab

CaSignalLogo
 
Featured in Biophysical Society TV (5-min film)


Ye Chen-Izu
Principal Investigator-Experiments

Leighton T. Izu
Principal Investigator-Modeling

 
 

Our Vision

“In few specialties of medicine are new promising drugs shown to be so much inferior to placebo and even worse, to increase mortality.”   –Sanderson, Editorial on SWORD and CAST trials


Combat Heart Diseases
  • Hypertension-induced arrhythmias
  • Muscular Dystrophy cardiomyopathy
  • Hypertrophic cardiomyopathy
  • Dilated cardiomyopathy

Why heart diseases remain the #1 killer without effective drug therapy?
The heart is a dynamic organ; the cardiomyocytes excitation-contraction is controlled by three dynamic systems — the electrical, the Ca2+ signalling, and the contractile system. Previous research and drug development often targeted a single molecule in a single system. However, because of the feedback interactions between these non-linear dynamic systems, a change in one system can engender unexpected changes in all systems, making the drug effect to be unpredictable. We envision that development of effective anti-arrhythmic drug therapies requires a paradigmatic shift from targeting a single molecule or a single system to a new strategy that embraces the integrated behaviour of all dynamical systems that control cardiac function and heart diseases.
Our interdisciplinary team combines molecular and cellular biology, chemistry, physics, and mathematical modelling to advance research in three aspects: (1) developing innovative technologies, (2) studying the fundamental mechano-chemo-electro-transduction mechanisms, and (3) developing new drug therapies to combat heart diseases.

Comments are closed.